Recall events
/
Event 85756
Event summary
Timeline bucket May 26, 2020
Product types Drug
Classifications Class III
Statuses Terminated
Recalling firm wording Aurobindo Pharma USA Inc.
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
2 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 2
Olanzapine Tablets, USP 2.5 mg, 30-count bottle, Rx only, Manufactured for: Prasco Laboratories Mason, OH 45040 USA, Manufactured by: Aurolife Pharma LLC Dayton, NJ 08810, NDC 66993-680-30
D-1314-2020
Recall number D-1314-2020
Initiated May 26, 2020
Classification Class III
Status Terminated
Quantity 13322 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Failed Impurities/ Degradation Specifications
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Failed Impurities/ Degradation Specifications
Code information Lot #: 561180046A1, Exp 8/2020
Distribution pattern U.S.A. Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[14623]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 2
Olanzapine Tablets, USP 7.5 mg, 30-count bottle, Rx only, Manufactured for: Prasco Laboratories Mason, OH 45040 USA, Manufactured by: Aurolife Pharma LLC Dayton, NJ 08810, NDC 66993-682-30
D-1315-2020
Recall number D-1315-2020
Initiated May 26, 2020
Classification Class III
Status Terminated
Quantity 7547 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Failed Impurities/ Degradation Specifications
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Failed Impurities/ Degradation Specifications
Code information Lot #: 563180012A1, Exp 8/2020
Distribution pattern U.S.A. Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[14794]
FDA event record
· Exact recall-number query on openFDA
